Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

.S. alone.

Recently published data also indicates that physicians only co-prescribe GI protective agents 27 percent of the time.  In addition, historical data has shown that, by the third prescription, over 60 percent of patients stop taking their prescribed GI co-therapy.  

About Horizon Pharma

Horizon Pharma, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation.   Horizon's product portfolio includes innovative therapies in early- and late-stage development that are designed to improve the efficacy, safety and quality of life for patients with chronic pain and inflammation.   Horizon's most advanced product is LODOTRA, a circadian cytokine modulator (CCM) for the treatment of the signs and symptoms of rheumatoid arthritis (RA), which has received a recommendation for granting of a national marketing authorization in certain Member States of the European Union.  L ODOTRA is already launched in Germany.   The company's lead development stage product is DUEXA, a novel, proprietary fixed-dose tablet combining one of the most prescribed NSAIDs in the world, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.   In two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), DUEXA was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal (GI) ulcers in patients with mild-to-moderate pain and arthritis.   The Company is financed by leading life-science investors Atlas Venture, Deutsche Bank AG, London, Essex Woodlands Healthcare Ventures, FirstMark Capital, Global Life Science Ventures, NGN Capital, Scale Ventures, Sutter Hill Ventures and TVM Capital.

For more info
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/rf4hfn/global ) ... Neurodegenerative Diseases Market 2015-2019" report to their ... to grow at a CAGR of 4.77% over ... the present scenario and the growth prospects of ... 2015-2019. To calculate the market size, the report ...
(Date:6/3/2015)... June 3, 2015  EIP Pharma LLC ( www.eippharma.com ... clinical development of VX-745 in Alzheimer,s disease (AD) is ... and potent inhibitor of the alpha isoform of the ... alpha). "Recent human genetic data demonstrate that ... with symptomatic Alzheimer,s, while the science also indicates the ...
(Date:6/3/2015)... , June 02, 2015 Research and ... the "Europe Ultrasound Devices Market - Growth, Trends ... offering. Currently, the European market is dominated ... of France and ... increasing incidences of chronic diseases in these regions. ...
Breaking Medicine Technology:Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3European Ultrasound Devices Market Report 2015-2019 2
... May 4, 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced ... months ended March 31, 2012. (Logo: ... reported a loss from continuing operations of $513,000, or ... 31, 2012 compared to income from continuing operations of ...
... (NASDAQ: AMGN ) will present at the Baird ... Four Seasons Hotel, Chicago, Ill., beginning at 8:20 a.m. Central ... Amgen, will present. Live audio of the presentation can be ... , under Investors. About Amgen ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
(Date:6/3/2015)... Raleigh, NC (PRWEB) June 03, 2015 ... on two biomarkers for mesothelioma and say the tried-and-true ... has just posted an article on the research. ... in the University’s National Center for Asbestos Related Diseases ... false positive results, it is still preferable to fibulin-3 ...
(Date:6/3/2015)... June 03, 2015 Sitting at a ... discomfort in the back, neck, shoulders and/or wrists. This ... injuries. In addition, recent research links sitting for long ... chronic diseases. Fortunately, three inventors from Oakville, Ontario, are ... a desk. , They have developed a prototype for ...
(Date:6/3/2015)... On Sunday, June 7, 2015, tens of ... their local communities to observe the 28th annual National ... and abroad will hold celebrations on this day to ... challenges of cancer survivorship, and to show the world ... rewarding, and inspiring.,  , National Cancer Survivors Day® is ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Fourroux Prosthetics, ... Duluth, GA will celebrate its grand opening with a ... The first prosthetic center of its kind in the ... family unmatched care and outcomes through use of patented ... CPO & CEO of Fourroux Prosthetics, states, “Our goal ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 These are ... sectors. The ever growing number of digital-first business are ... There is now a serious need for traditional businesses ... way they operate and deliver their services. On ... partnerships between incumbents and technology start-ups, to bring new ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... The Cardinal Health Foundation today announced that it ... a $100,000 grant to create education and outreach programs ... medication abuse and misuse in their communities. , According ... quarter of all Ohio high school students have reported ...
... LONDON, October 28 Even though no-one wants to admit it,the countdown ... at the,ubiquitous Christmas Party then follow the realbuzz.com guide to a healthier,you. ... living go out,the window, so now,s the time to turn your body ... be realbuzz.com if we didn,t offer this piece of,advice to start with! ...
... ... keys to exceptional marketing performance at your fingertips with his new web seminar hosted ... them will help pharmaceutical marketers understand what they can do to improve the effectiveness ... ...
... Ill., Oct. 28 Understanding the needs of patients ... providers, including enhancing safety and helping to stem the ... fact, many academic medical centers are turning to implementation ... quality of care for patients. , The Institute ...
... Oct. 27 Dr. Michael Feiz , lead surgeon at ... Lap Band surgeries than any other doctor. For ... is the answer they have been looking for to shed the ... with almost no scarring, Lap Band surgery has the ...
... Oct. 27 The St. Louis Cardinals, new hire of ... coach sends a message to all baseball and young people ... ," former White House drug policy spokesman Bob Weiner said ... the drugs? When McGwire used Andro (Androstenedione), now banned, he ...
Cached Medicine News:Health News:Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse 2Health News:The Countdown to Christmas - The realbuzz.com Guide to a Healthier You! 2Health News:5 Steps to Pharmaceutical Marketing Happiness 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 3Health News:Beverly Hills Doctor (drfeiz.com) Performs the World's Most Lap Band Surgeries 2Health News:Mark McGwire's Message: Cheat, Do Drugs, Cover Up When Congress Investigates, Says Ex-White House Drug Spokesman Bob Weiner; World Series Should Test Both Teams During Games 2
Designated most popular model or size. 3 mm tip....
Designated most popular model or size. Double-ended. 2 mm wide....
Designated most popular model or size. Slightly angled, 2 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: